R & D

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%

 This material is intended to notify the press release issued on May 26 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.